Sponsored

Prescient Therapeutics (ASX:PTX) announces US-based Dr Ellen Feigal as new inclusion to Board

May 15, 2023 11:57 AM +04 | By Ankit Sethi

Highlights

  • Dr Ellen Feigal is serving on the Boards of NASDAQ-listed biotechnology companies Xencor Inc, and NextCure
  • She has been included in Prescient Therapeutics' Board as a US-based independent, Non-Executive Director
  • Dr Feigal has issued a statement saying she would "guide the business through the next phase of its growth"
  • Chairman Steve Engle has lauded the “strong track record” of Dr Feigal in commercialisation of new cell-based treatments in the US and globally

ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr Ellen Feigal to PTX's Board. Notably, Dr Feigal is an experienced pharma executive and has been onboarded as Prescient's US-based independent, Non-Executive Director. The effective date of her appointment is 15 May 2023.

Prescient Therapeutics is into the development of personalised therapies for treatment of cancer. Its targeted therapies include PTX-100 (blocks cancer growth enzyme geranylgeranyl transferase-1), and PTX 200 (inhibits tumour survival pathway Akt), while Prescient’s cell therapies include OmniCAR, and CellPryme-M and CellPryme-A.

Source: Company update 

More

The most recent development at the oncology company is related to the appointment of experienced pharma executive, Dr Ellen Feigal, to the company's Board. Dr Feigal brings to the table her expertise in development, commercialisation, and regulatory procedural aspects of cell therapies, hematology, and oncology. She has worked in leadership roles in industry as well as in academia and non-profits. 

Presently at NDA Partners LLC in the capacity of a Partner and Head of the Biologics practice, she oversees designing and implementation of product development and regulatory strategies. Her work here relates to cell therapies, medical imaging, and other related aspects. Dr Feigal also teaches FDA drug law and medical research ethics and law at the Sandra Day O’Connor College of Law, Arizona State University. 

Source: Company update 

Formerly, she worked as the Senior Vice President at California Institute of Regenerative Medicine (a foundation working toward developing new disease modifying treatments for chronic diseases). She has also worked in senior roles at the Amgen Inc (NASDAQ:AMGN), the Translational Genomics Research Institute, and the National Cancer Institute.

Dr Feigal is on the Board of Xencor Inc (NASDAQ:XNCR), which is developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, besides being a board member at NextCure (NASDAQ:NXTC), which is developing new immunotherapies for the treatment of cancer.

Prescient's shares on ASX traded at AU$0.085 (market cap over AU$71 million) on 15 May 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.